These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 17005394

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities.
    da Costa Leite LF, Veras Mourão RH, de Lima Mdo C, Galdino SL, Hernandes MZ, de Assis Rocha Neves F, Vidal S, Barbe J, da Rocha Pitta I.
    Eur J Med Chem; 2007 Oct; 42(10):1263-71. PubMed ID: 17448573
    [Abstract] [Full Text] [Related]

  • 3. 1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility.
    Henke BR.
    Prog Med Chem; 2004 Oct; 42():1-53. PubMed ID: 15003718
    [No Abstract] [Full Text] [Related]

  • 4. PPAR and Pain.
    Maeda T, Kishioka S.
    Int Rev Neurobiol; 2009 Oct; 85():165-77. PubMed ID: 19607969
    [Abstract] [Full Text] [Related]

  • 5. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
    Rudolph J, Chen L, Majumdar D, Bullock WH, Burns M, Claus T, Dela Cruz FE, Daly M, Ehrgott FJ, Johnson JS, Livingston JN, Schoenleber RW, Shapiro J, Yang L, Tsutsumi M, Ma X.
    J Med Chem; 2007 Mar 08; 50(5):984-1000. PubMed ID: 17274610
    [Abstract] [Full Text] [Related]

  • 6. [PPAR receptors at the crossroads of obesity, diabetes and cardiovascular diseases].
    Gilde A, Fruchart JC, Staels B.
    Journ Annu Diabetol Hotel Dieu; 2007 Mar 08; ():21-38. PubMed ID: 18610756
    [No Abstract] [Full Text] [Related]

  • 7. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.
    Zieleniak A, Wójcik M, Woźniak LA.
    Arch Immunol Ther Exp (Warsz); 2008 Mar 08; 56(5):331-45. PubMed ID: 18836859
    [Abstract] [Full Text] [Related]

  • 8. [Peroxisome proliferator activated receptor ligands and angiogenesis].
    Sato M.
    Nihon Rinsho; 2005 Apr 08; 63(4):603-8. PubMed ID: 15828227
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists.
    Lu Y, Guo Z, Guo Y, Feng J, Chu F.
    Bioorg Med Chem Lett; 2006 Feb 15; 16(4):915-9. PubMed ID: 16300944
    [Abstract] [Full Text] [Related]

  • 10. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
    Henry JR, Li Y, Warshawsky AM, Brozinick JT, Hawkins ED, Misener EA, Briere DA, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Ajamie RT, Wilken B, Devanarayan V.
    Bioorg Med Chem Lett; 2006 Dec 15; 16(24):6293-7. PubMed ID: 17005393
    [Abstract] [Full Text] [Related]

  • 11. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F, Jaber LA, Berlie HD, O'Connell MB.
    Ann Pharmacother; 2007 Jun 15; 41(6):973-83. PubMed ID: 17519293
    [Abstract] [Full Text] [Related]

  • 12. Selective PPAR agonists for the treatment of type 2 diabetes.
    Nehlin JO, Mogensen JP, Petterson I, Jeppesen L, Fleckner J, Wulff EM, Sauerberg P.
    Ann N Y Acad Sci; 2006 May 15; 1067():448-53. PubMed ID: 16804025
    [Abstract] [Full Text] [Related]

  • 13. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
    Matin A, Gavande N, Kim MS, Yang NX, Salam NK, Hanrahan JR, Roubin RH, Hibbs DE.
    J Med Chem; 2009 Nov 12; 52(21):6835-50. PubMed ID: 19807106
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P, Rose M, Singh M.
    Pharmacology; 2007 Nov 12; 80(1):1-10. PubMed ID: 17496434
    [Abstract] [Full Text] [Related]

  • 16. Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.
    Cantin LD, Liang S, Ogutu H, Iwuagwu CI, Boakye K, Bullock WH, Burns M, Clark R, Claus T, delaCruz FE, Daly M, Ehrgott FJ, Johnson JS, Keiper C, Livingston JN, Schoenleber RW, Shapiro J, Town C, Yang L, Tsutsumi M, Ma X.
    Bioorg Med Chem Lett; 2007 Feb 15; 17(4):1056-61. PubMed ID: 17157013
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
    Makadia P, Shah SR, Pingali H, Zaware P, Patel D, Pola S, Thube B, Priyadarshini P, Suthar D, Shah M, Giri S, Trivedi C, Jain M, Patel P, Bahekar R.
    Bioorg Med Chem; 2011 Jan 15; 19(2):771-82. PubMed ID: 21215640
    [Abstract] [Full Text] [Related]

  • 19. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B, Staels B.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec 15; 21(4):687-710. PubMed ID: 18054742
    [Abstract] [Full Text] [Related]

  • 20. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism.
    Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G, Pecorini G, Stigliano E, Smith RC, Angelini F, Castellot JJ, Pola R.
    Diabetes; 2008 May 15; 57(5):1394-404. PubMed ID: 18268046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.